PRESS RELEASES

Date Title and Summary View
Toggle Summary New RNAi Approach for In Vivo Therapeutic Silencing of MicroRNAs is Demonstrated by Alnylam and Rockefeller University Scientists
Findings Published in Nature Show Potential of Targeting MicroRNAs to Treat Diseases
View HTML
Toggle Summary Alnylam and Isis License Intellectual Property for MicroRNA Gene Involved in Hepatitis C Viral Infection
Role of MicroRNA-122 in Hepatitis C Infection Published in Science
View HTML
Toggle Summary Alnylam and Isis Receive Exclusive License to Key microRNA Patents for Therapeutic Applications
Alnylam and Isis Receive Exclusive License to Key microRNA Patents for Therapeutic Applications Intellectual Property From Max Planck Society Strengthens Companies’ Leadership Positions In RNA-Based Drug Discovery and Development CAMBRIDGE, Mass., and CARLSBAD, Calif., Oct.
View HTML